(Q38075499)

28 August 2017

1 reference

title

Metastatic gastric cancer treatment: a little slow but worthy progress (English)

1 reference

28 August 2017

Ozkan Kanat

1

1 reference

28 August 2017

Bert H O'Neil

series ordinal

2

1 reference

28 August 2017

publication date

20 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

30

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

464

1 reference

28 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Management of advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Disparities in gastric cancer chemotherapy between the East and West

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Chemotherapy for metastatic gastric cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Advanced gastric cancer--slow but steady progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Chemotherapy for metastatic disease: review from JCOG trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Past and present achievements, and future direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

The role of S-1 in the treatment of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Chemotherapy for metastatic gastric cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Chemotherapy for advanced gastric cancer: across the years for a standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Docetaxel: its role in current and future treatments for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Systemic therapy for advanced gastric cancer: a clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Anti-HER agents in gastric cancer: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

The ErbB receptor tyrosine family as signal integrators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

The epidermal growth factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Targeted therapies in the treatment of gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

The angiogenic switch in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Pro-angiogenic cytokines and their role in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

The role of antiangiogenesis therapy: bevacizumab and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0464-4

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma

21 January 2018

1 reference

12 December 2020

Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas

1 reference

12 December 2020

Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas

1 reference

12 December 2020

Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.

1 reference

12 December 2020

Gastric cancer in Turkey-a bridge between west and East.

1 reference

12 December 2020

Prognostic value of vascular endothelial growth factor expression in gastric carcinoma

1 reference

12 December 2020

Latest developments and emerging treatment options in the management of stomach cancer

1 reference

12 December 2020

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

1 reference

12 December 2020

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

1 reference

12 December 2020

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab

1 reference

12 December 2020

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

12 December 2020

Diverse eastern and Western approaches to the management of gastric cancer.

1 reference

12 December 2020

Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients

1 reference

12 December 2020

Her-2/neu testing and therapy in gastroesophageal adenocarcinoma

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020

10.1007/S12032-013-0464-4

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1013179361

0 references

Fatcat ID

release_wfrz44djjngwnapjmutedjqqsy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wfrz44djjngwnapjmutedjqqsy

24 November 2022

mapped directly with Wikidata item

1 reference